Interleukin-1 Blockade In Recently Decompensated Heart Failure - 2
Status:
Recruiting
Trial end date:
2024-09-01
Target enrollment:
Participant gender:
Summary
REDHART2 is a randomized, double-blinded, placebo-controlled trial to determine the effects
of Anakinra on peak aerobic exercise capacity measured with a cardiopulmonary test after 24
weeks in patients with recently decompensated systolic heart failure and increased systemic
inflammation.